DigestRedComo funciona
Red
/
Empresas
Te
No verificado

Teva Pharmaceutical Industries Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

128 Comunicados de prensa

Ver todos los comunicados de prensa
18/09/2026
Farmacéutica
Medicina Salud Bienestar
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
18/09/2026
Farmacéutica
Medicina Salud Bienestar
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
18/09/2026
Farmacéutica
Anuncios breves
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
16/09/2026
Farmacéutica
Medicina Salud Bienestar
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
14/09/2026
Farmacéutica
Finanzas
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
10/09/2026
Farmacéutica
Fondos de inversión
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
07/09/2026
Farmacéutica
Finanzas
Teva Announces Launch of Offering of Senior Notes
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
04/09/2026
Farmacéutica
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
02/09/2026
Farmacéutica
Medicina Salud Bienestar
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
01/09/2026
Farmacéutica
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0